Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019-12
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
N05CM25
|
| gptkbp:CASNumber |
1369764-02-2
|
| gptkbp:contraindication |
narcolepsy
|
| gptkbp:drugClass |
orexin receptor antagonist
|
| gptkbp:genericName |
gptkb:lemborexant
|
| gptkbp:halfLife |
17 to 19 hours
|
| gptkbp:hasMolecularFormula |
C22H20F2N4O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dayvigo
|
| gptkbp:legalStatus |
Schedule IV (US)
|
| gptkbp:manufacturer |
gptkb:Eisai_Co.,_Ltd.
|
| gptkbp:mechanismOfAction |
dual orexin receptor antagonist
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
headache somnolence |
| gptkbp:usedFor |
treatment of insomnia
|
| gptkbp:bfsParent |
gptkb:Eisai
|
| gptkbp:bfsLayer |
6
|